DEA Prepares to Restrict Telehealth Prescribing: What It Means for Addiction Treatment Access

The Drug Enforcement Administration is finalizing a rule that could fundamentally reshape how Americans access addiction treatment through telehealth. According to leaked details reported by multiple healthcare publications, the draft regulation—expected in September 2026—would impose stricter limitations on remote prescribing of controlled substances than many patient advocates had anticipated.

The most consequential provision would require that half of all prescriptions for controlled substances be preceded by an in-person medical evaluation. For the addiction treatment community, this requirement arrives at a particularly sensitive moment. Telehealth prescribing of buprenorphine, a medication used to treat opioid use disorder, expanded dramatically during the COVID-19 pandemic after the DEA waived certain requirements of the Ryan Haight Online Pharmacy Consumer Protection Act. That waiver, extended multiple times, is now set to expire, and the proposed rule suggests a more restrictive framework than the temporary flexibilities allowed.

The Scope of the Proposed Restrictions

The leaked draft indicates the DEA intends to narrow the categories of medications eligible for telehealth prescription while maintaining the in-person visit mandate. While the full medication list remains undisclosed, the framework would likely affect Schedule II through V controlled substances, which encompass the full range of medications used in addiction treatment—from buprenorphine and methadone to certain anxiety medications that patients in recovery sometimes require.

Healthcare lobbyists familiar with the drafting process have indicated that the Alliance for Connected Care, a prominent telehealth advocacy organization, is already preparing intervention letters to the White House and congressional leadership. Their argument centers on a practical concern: the United States lacks a unified national prescription drug monitoring program that would allow providers to verify patient histories across state lines. Without such infrastructure, advocates contend, an abrupt shift to in-person requirements could disrupt care for hundreds of thousands of patients who began treatment through telehealth channels during the pandemic.

Why the Timing Matters

The DEA's rulemaking arrives as the healthcare system is still absorbing the implications of the MAT Act of 2022, which eliminated the X-waiver requirement that had previously restricted which clinicians could prescribe buprenorphine for opioid use disorder. That change was designed to expand access. The new telehealth restrictions, if implemented as described, could create a countervailing pressure—expanding the pool of eligible prescribers while simultaneously constraining the modalities through which they can reach patients.

For rural communities, the tension is especially acute. A patient in a frontier county might now have a local primary care physician newly authorized to prescribe buprenorphine but find that the same physician cannot continue their treatment via telehealth without an initial in-person encounter. The geography that made access difficult before the pandemic would reassert itself.

The Done Global Case and Its Shadow

The regulatory climate has been shaped in part by enforcement actions against telehealth companies accused of operating as pill mills. The April 2026 sentencing of Done Global executives—marking the Department of Justice's first criminal prosecution of a digital health company for drug distribution via telemedicine—has intensified scrutiny of remote prescribing practices. Prosecutors emphasized that telehealth abuse would be met with accountability, and the verdict has been cited by policymakers as evidence that tighter controls are necessary.

Yet addiction medicine specialists distinguish between the stimulant prescribing patterns that characterized the Done Global case and the established protocols for medication-assisted treatment of opioid use disorder. Buprenorphine, unlike the Adderall and Ritalin at issue in the Done prosecution, has a ceiling effect on respiratory depression and is generally considered to have lower diversion potential than full agonist opioids. Whether the DEA's rulemaking will reflect these clinical distinctions remains unclear.

What Patients and Providers Should Watch

Several key questions will determine the rule's ultimate impact. The first is whether the DEA will establish exceptions for medication-assisted treatment or whether buprenorphine will be subject to the same in-person requirements as other controlled substances. The second is how the agency will define the relationship between a provider and patient—specifically, whether patients who established care during the waiver period will be grandfathered into continued telehealth access.

The third question concerns the timeline. With the rule expected in September 2026, stakeholders will have a comment period to influence the final language. The Alliance for Connected Care is reportedly seeking a two-year extension of current flexibilities to allow time for infrastructure development and patient transitions. Congressional action remains possible, particularly if the proposed rule generates sufficient backlash from rural healthcare advocates and patient groups.

For individuals currently receiving buprenorphine through telehealth, the immediate message is to establish in-person relationships with local providers where possible. The regulatory landscape is shifting, and the flexibility that characterized pandemic-era addiction treatment appears to be narrowing. Whether the pendulum has swung too far—and whether Congress or the courts will intervene—will become clearer in the months ahead.